

Special Issue

Advancing Cardio-Oncology: Mechanisms of Cardiotoxicity and Therapeutic Options for Old and New Anticancer Drugs

Message from the Guest Editor

The incidence of cancer is growing worldwide. Nonetheless, the life expectancy of cancer patients continues to improve due to advancements in early diagnosis and the development of both established and novel therapies. However, the cardiotoxicity associated with anticancer treatments remains a leading cause of death and morbidity in cancer patients. This growing burden underscores the critical importance of cardio-oncology as a focal clinical and scientific field. A major future challenge in cardiovascular medicine lies in elucidating the molecular and immunological mechanisms of cardiotoxicity associated with these therapies, enabling the development of more precise diagnostic tools, effective therapeutic strategies, and personalized approaches to mitigate risks. This Special Issue aims to bring together the latest findings in cardio-oncology. These contributions will highlight novel mechanisms underlying cardiac remodeling and dysfunction caused by anticancer therapies and explore innovative pharmacological and non-pharmacological solutions to address these challenges.

Guest Editor

Dr. Vera Marisa Costa

UCIBIO, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal

Deadline for manuscript submissions

closed (31 July 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/227547

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)